This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Where a manufacturer publishes a supply statement, that document is more reliable than any aggregation of individual experiences.
On balance I think that is right, and I would not bet much on it.
What I would check first on managing an unplanned gap is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
Practical experience of managing an unplanned gap, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Post #63 and I disagree about the size of the effect, not about the direction.
Two sentences on managing an unplanned gap and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Managing an unplanned gap is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
That is clearer than the version I had in my head. Thank you.
Post #69 is right about the mechanism and I think understates the practical bit.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Post #74 answers the question as asked. The question underneath it is different.
Shortage-driven price movement is real and is a separate question from availability.
This has been discussed before and I could not find the thread, so, again.
Noted, and thank you for writing it out rather than summarising it.
The useful distinction on managing an unplanned gap is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Speaking only to managing an unplanned gap as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
Confirming post #81 from a second method, which matters more than confirming it from a second person.
Managing an unplanned gap sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Same experience here, different supplier, so it is at least not unique to one of them.
Managing an unplanned gap would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
On post #85 — agreed on the reasoning, with one qualification.
Where a manufacturer publishes a supply statement, that document is more reliable than any aggregation of individual experiences.
Post #85 put the caveat in the right place and I want to underline it.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Two sources, same conclusion, and I could not rule out that one copied the other.
Agreed on all of that, and I have nothing to add to it.